Trial Profile
A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs PIM 447 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 20 Jun 2019 Status changed from active, no longer recruiting to completed.
- 15 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 20 Apr 2018 Planned primary completion date changed from 30 Mar 2018 to 3 Sep 2019.